GlassScriptPhysician profile
John K Wong
NPI 1336436500
$24,530.10
in general payments reported to CMS, 2019-2025
81 companies · $8,223 in 2025
The $8,223 reported for 2025 was more than what 87% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.49 · 2021: $1,636 · 2022: $3,678 · 2023: $5,354 · 2024: $5,621 · 2025: $8,223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $17K · Long Term Medical Supply Or Device Loan: $2,098 · Education: $401.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $16,699.53 |
| Long Term Medical Supply Or Device Loan | $2,098.14 |
| Education | $400.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $3,730.42 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,332.68 | 2021-2025 | Calquence, Imfinzi, Enhertu |
| Pfizer INC. | $1,247.41 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $1,235.44 | 2021-2025 | Keytruda, Welireg, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $1,188.30 | 2021-2025 | Opdivo, Opdualag |
| Celgene Corporation | $918.92 | 2022-2025 | Reblozyl, Pomalyst, Opdualag |
| Eisai INC. | $859.93 | 2021-2025 | |
| Seagen INC. | $732.63 | 2021-2025 | Adcetris, Tivdak |
| Janssen Biotech, INC. | $717.32 | 2021-2025 | Talvey, Darzalex, Tecvayli |
| Exelixis INC. | $697.26 | 2021-2025 | Cabometyx |
| Daiichi Sankyo INC. | $609.63 | 2022-2025 | Enhertu, Injectafer, Vanflyta |
| Abbvie INC. | $591.38 | 2021-2025 | Venclexta |
| Beigene USA, INC. | $583.43 | 2021-2025 | Brukinsa, Tevimbra |
| Incyte Corporation | $580.08 | 2021-2025 | Monjuvi, Jakafi, Pemazyre |
| Genentech USA, INC. | $536.77 | 2022-2025 | Tecentriq, Polivy, Lunsumio |
Show all 80 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $488.35 | 2021-2025 | Trodelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $432.83 | 2021-2025 | Fruzaqla, Alunbrig, Ninlaro |
| Regeneron Healthcare Solutions, INC. | $416.59 | 2021-2025 | Libtayo |
| Genzyme Corporation | $400.32 | 2021-2025 | |
| Amgen INC. | $397.46 | 2021-2025 | Lumakras, Nplate, Xgeva |
| Pharmacyclics LLC, An Abbvie Company | $346.74 | 2021-2023 | Imbruvica, Epkinly |
| Taiho Oncology, INC. | $326.11 | 2023-2025 | |
| Myovant Sciences INC. | $302.43 | 2021-2022 | |
| Pharmaessentia USA Corporation | $287.95 | 2023-2025 | Besremi |
| Coherus Oncology, INC. | $276.98 | 2021-2025 | Loqtorzi, Udenyca |
| Karyopharm Therapeutics INC. | $269.64 | 2021-2025 | Xpovio |
| Rigel Pharmaceuticals, INC. | $252.88 | 2022-2025 | Rezlidhia, Tavalisse, Gavreto |
| Aveo Pharmaceuticals, INC. | $243.14 | 2021-2025 | Fotivda |
| Astellas Pharma US INC | $227.74 | 2022-2025 | Padcev, Xtandi |
| Array Biopharma INC | $222.20 | 2022-2025 | Braftovi, Mektovi, Lorbrena |
| Puma Biotechnology, INC. | $211.91 | 2021-2025 | |
| Adc Therapeutics America, INC. | $197.66 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $189.45 | 2021-2025 | Ultomiris |
| Boehringer Ingelheim Pharmaceuticals, INC. | $183.96 | 2022-2025 | Gilotrif |
| Glaxosmithkline, LLC. | $178.29 | 2024-2025 | Ojjaara, Jemperli, Blenrep |
| Lilly USA, LLC | $164.58 | 2023-2025 | Jaypirca, Verzenio, Retevmo |
| Genmab U.S., INC. | $163.90 | 2023-2025 | Epkinly |
| Pharmacosmos Therapeutics INC. | $159.23 | 2021-2025 | Monoferric |
| Sobi, INC | $153.30 | 2021-2025 | |
| Beone Medicines USA, INC. | $132.37 | 2025 | Tevimbra, Brukinsa |
| Emd Serono, INC. | $132.21 | 2022-2025 | Bavencio |
| Adaptive Biotechnologies Corporation | $131.77 | 2024-2025 | Clonoseq |
| Ipsen Biopharmaceuticals, INC | $128.13 | 2023-2025 | Onivyde, Somatuline Depot |
| Morphosys, US INC. | $101.59 | 2021-2023 | Monjuvi |
| Caris Mpi, INC. | $100.97 | 2025 | Mi Cancer Seek |
| Bayer Healthcare Pharmaceuticals INC. | $97.53 | 2025 | |
| Stemline Therapeutics INC. | $96.57 | 2023-2025 | Orserdu |
| Tersera Therapeutics LLC | $85.24 | 2022-2025 | Quzyttir |
| Azurity Pharmaceuticals, INC. | $81.68 | 2025 | Danziten |
| Springworks Therapeutics, INC. | $81.04 | 2024 | Ogsiveo |
| Jazz Pharmaceuticals INC. | $79.29 | 2024-2025 | |
| Geron Corporation | $78.67 | 2024-2025 | Rytelo |
| Iovance Biotherapeutics, INC. | $78.47 | 2025 | Amtagvi |
| Acrotech Biopharma INC. | $77.18 | 2023-2025 | Beleodaq |
| Kite Pharma, INC. | $71.92 | 2022-2023 | Yescarta |
| Epizyme, INC. | $70.15 | 2021 | |
| Deciphera Pharmaceuticals INC. | $65.25 | 2023-2025 | Qinlock, Romvimza |
| Agios Pharmaceuticals, INC. | $64.43 | 2023-2025 | Pyrukynd |
| Servier Pharmaceuticals LLC | $61.77 | 2021-2022 | |
| Blueprint Medicines Corporation | $61.19 | 2024-2025 | Ayvakit |
| Boston Scientific Corporation | $58.17 | 2025 | Therasphere Y90 Glass Microspheres 7.0 Gbq (US Commercial), Therasphere Y90 Glass Microspheres 10 Gbq |
| Sumitomo Pharma America, INC. | $56.42 | 2023 | Orgovyx |
| Kyowa Kirin, INC. | $55.88 | 2022-2025 | Poteligeo |
| Recordati_rare_diseases_inc. | $55.37 | 2025 | Sylvant, Enjaymo |
| Tempus Ai, INC | $44.81 | 2024 | |
| Alnylam Pharmaceuticals INC. | $42.91 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $33.21 | 2024-2025 | Sancuso |
| Dendreon Pharmaceuticals LLC | $29.87 | 2024 | Provenge |
| Genentech, INC. | $23.62 | 2023 | Columvi, Lunsumio |
| Accord Healthcare, INC. | $22.91 | 2025 | |
| Janssen Pharmaceuticals, INC | $21.92 | 2024 | Xarelto |
| Legend Biotech USA INC. | $21.21 | 2025 | Carvykti |
| Mirati Therapeutics, INC. | $19.94 | 2023 | Krazati |
| Fresenius Kabi USA, LLC | $18.69 | 2025 | |
| Helsinn Therapeutics (U.S.), INC. | $18.41 | 2025 | Akynzeo |
| Apellis Pharmaceuticals, INC. | $18.16 | 2025 | Empaveli |
| Sirtex Medical INC | $17.47 | 2023 | Sir-Spheres Microspheres |
| Organon LLC | $15.04 | 2024 | |
| Cti Biopharma Corp. | $11.73 | 2022 | |
| Eusa Pharma (US) LLC | $11.70 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
Kisqali $2,600Keytruda $875Lenvima $671Reblozyl $668Adcetris $513Imbruvica $511Epkinly $503Enhertu $498Opdivo $477Cabometyx $463Brukinsa $407Elrexfio $376Xtandi $369Talvey $348Pluvicto $345Lonsurf $326Inqovi $326Darzalex $323Calquence $320Besremi $288Tecvayli $277Opdualag $269Monjuvi $267Imfinzi $265Bosulif $263Tecentriq $238Libtayo $231Rezlidhia $218Tavalisse $218Trodelvy $214Padcev $202Lynparza $197Fotivda $197Ibrance $195Xpovio $192Sarclisa $190Piqray $184Welireg $178Zynlonta $177Mektovi $176Braftovi $176Polivy $171Fruzaqla $165Verzenio $165Jaypirca $165Jakafi $163Carvykti $163Ultomiris $162Orgovyx $152Lorbrena $151Tukysa $141Talzenna $140Lunsumio $135Monoferric $134Clonoseq $132Lutathera $129Onivyde $128Somatuline Depot $128Venclexta $117Ayvakit $117Tevimbra $113Pomalyst $110Inlyta $106Udenyca $104Tagrisso $103Mi Cancer Seek $101Gavreto $98.09Nubeqa $97.53Alunbrig $97.33Orserdu $96.57Tivdak $95.07Loqtorzi $92.40Pemazyre $91.38Wayrilz $89.81Rybrevant $88.74Ojjaara $83.31Danziten $81.68Zepzelca $79.29Doptelet $79.11Jemperli $78.78Rytelo $78.67Amtagvi $78.47Elahere $78.10Zynyz $77.66Beleodaq $77.18Columvi $76.39Fabhalta $72.90Ninlaro $71.93Retevmo $68.30Promacta $66.33Qinlock $65.25Pyrukynd $64.43Scemblix $62.30Injectafer $57.09Ogsiveo $54.79Vanflyta $50.05Besponsa $47.85Gilotrif $47.70Erleada $40.48Akeega $40.48
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Wong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.